Evidence map›Paper›PMID 19779958›Full record

ArticleThe journal of headache and pain2009

Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment.

Peer C Tfelt-Hansen

Open access · hybridAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.Annals of clinical and translational neurology · 2015
    Article
  3. Using telcagepant for the acute treatment of migraine.Current pain and headache reports · 2010
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Peer C Tfelt-HansenDanish Headache Centre, Glostrup Hospital, Glostrup, Denmark. ptha@glo.regionh.dk
University of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcitonin gene-related peptide (CGRP) receptor antagonists are a new treatment principle in acute migraine attacks. Intravenous olcegepant 2.5 mg resulted in 66% headache relief after 2 h, whereas subcutaneous sumatriptan resulted in 81-92% headache relief after 2 h. The intrinsic activity of a parenteral triptan, a 5HT(1B/1D) receptor agonist, is thus higher than the maximum effect of the parenteral CGRP receptor antagonist olcegepant. For the orally bioavailable CGRP antagonist telcagepant 300 mg, the headache relief was only 55% in one phase III study. These results indicate that CGRP receptor antagonism results in success in the acute treatment of migraine in only a certain fraction of the patients.

Indexed as

Calcitonin Gene-Related Peptide Receptor AntagonistsAzepinesCalcitonin Gene-Related PeptideCerebral ArteriesClinical Trials as TopicDipeptidesHumansImidazolesMigraine DisordersPiperazinesQuinazolinesReceptors, Calcitonin Gene-Related PeptideSerotonin Receptor AgonistsTreatment FailureTryptaminesAzepinesCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsDipeptidesImidazolesolcegepantPiperazinesQuinazolinesReceptors, Calcitonin Gene-Related PeptideSerotonin Receptor AgoniststelcagepantTryptamines

Identifiers

PMID19779958
PMCPMC3476212
OpenAlexW2026753753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.